Autoimmune Hepatitis: What to Do When First-Line Induction Fails to Achieve Biochemical Remission

First-line induction for autoimmune hepatitis aims at complete biochemical remission within 6–12 months. When that target is not reached — or when first-line agents are not tolerated — a structured second-line strategy is required.

Previous Treatment — Failure Condition

First-line induction with corticosteroids (predniso(lo)ne) combined with azathioprine or mycophenolate mofetil did not achieve complete biochemical response — normalisation of AST, ALT, and IgG levels — within 6–12 months of treatment initiation, or was complicated by intolerance or significant side effects requiring a change of approach.

Treatment Goal

Complete biochemical response: normalisation of AST, ALT, and IgG levels.

Second-Line Approach (Partial Overview)

Second-line management addresses two distinct situations: patients who cannot tolerate thiopurines, for whom specific alternative immunosuppressive agents are indicated, and patients with an insufficient response, for whom targeted optimisation of the existing regimen is explored before any escalation to third-line therapies.

Full agent selection, optimisation criteria, and sequencing algorithm available in the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jhep.2025.03.017

MMF is recommended as the second-line treatment of choice in patients with intolerance or side effects to thiopurines (LoE 2, strong recommendation, strong consensus).
MP or TG can be used in patients with intolerance to azathioprine (LoE 4, weak recommendation, strong consensus).
After exclusion of non-adherence, intensification/optimisation of immunosuppression by increasing the dose of azathioprine up to 2 mg/kg/day (when 6-MMP is appropriately low) is recommended (LoE 3, strong recommendation, strong consensus).
Addition of allopurinol (contraindicated in pregnancy) and reduction of the azathioprine dose to 25% (when 6-MMP is disproportionately increased) can be suggested as an alternative to the previous recommendation (LoE 3, weak recommendation, strong consensus).
MMF may be used before initiating third-line therapies after unsuccessful intensification/optimisation of azathioprine-related therapies (LoE 2, weak recommendation, consensus).
According to a recent report by the IAIHG,163 CBR was defined as normalisation of AST, ALT, and IgG levels no later than 6 months after treatment initiation (Table 7).

View source ↗